Evidence map›Paper›PMID 41036145›Full record

Observational studyFrontiers in endocrinology2025

The role of SHR in risk stratification for long-term prognosis in patients with coronary artery disease: findings from a large cohort study.

Wei Xu, Xiang Wang, Chenxi Xia, Xuyang Meng, Yi Li, Yejing Zhao, Chenguang Yang, Baoyu Feng, Zinan Zhao, Fang Wang

Abstract readObservational Study
In one paragraph

Observational study in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wei Xu *Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiang Wang *Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Chenxi Xia *Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Xuyang MengDepartment of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Yi LiDepartment of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Yejing ZhaoDepartment of Gerontology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Chenguang YangDepartment of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Baoyu FengDepartment of Clinical Trial Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Zinan ZhaoDepartment of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing, China.
Fang WangDepartment of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recently, the Stress Hyperglycemia Ratio (SHR) - which integrates acute increases in blood glucose with long-term glycemic control levels - has shown independent predictive value for adverse events in patients with acute coronary syndrome (ACS). However, the long-term prognostic significance of SHR in a broader population of coronary artery disease (CAD) remains unclear. This study aimed to explore the role of SHR in prediction of long-term prognosis of CAD. Methods: In this cohort study, we enrolled 23,591 participants diagnosed with CAD from January, 2016, to December, 2021 in Beijing Hospital. After excluding patients lacking data, with cancers, or missing follow-ups, 7,162 patients were finally enrolled into the analyses. The SHR was calculated using the following equation: SHR = admission glucose (mmol/L)/(1.59 × HbA1c [%]-2.59). The 7,162 participants were divided into three groups based on SHR tertiles: Tertile 1 (SHR ≤ 0.72, n=2391), Tertile 2 (0.73≤SHR ≤ 0.82, n=2388), and Tertile 3 group (SHR≥0.83, n=2383). The primary endpoint was all-cause mortality and cardiovascular death (CVD), while the second endpoint was major adverse cardiovascular events (MACE). The median follow-up was 28 months. Results: Our results suggest that SHR was significantly associated with increased risks of long-term all-cause death, CVD death, and MACE. The Kaplan-Meier curves revealed that the highest tertile (T3) group had the highest risk of all-cause death, CVD death, and MACE, while the lowest tertile (T1) group had the lowest risk (all log-rank P < 0.05). After adjusting risk factors, the results of cox regression analyses showed that SHR was significantly associated with all three outcomes (all P < 0.05). For all-cause death, SHR was associated with an increased risk of all-cause death in the fully adjusted model (Model 3: HR = 2.52, 95% CI: 1.57 - 4.05, P < 0.001). Compared to the lowest tertile (T1), participants in the highest tertile (T3) had a likely higher risk of all-cause death (HR = 1.40, 95% CI: 1.05 - 1.87, P = 0.021). SHR also demonstrated a positive association with CVD death (Model 3: HR = 2.87, 95% CI: 1.22 - 6.76, P = 0.016), and participants in T3 had a significantly higher risk of CVD death compared to T1 (HR = 1.94, 95% CI: 1.11 - 3.40, P = 0.021). Additionally, SHR was also independently associated with MACE (Model 3: HR = 1.70, 95% CI: 1.21 - 2.38, P = 0.002). The risk of MACE was significantly higher in T3 compared to T1 (HR = 1.21, 95% CI: 1.02 - 1.45, P = 0.031). The restricted cubic spline (RCS) analysis further confirmed a positive nonlinear association between SHR and these adverse outcomes (all-cause death, CVD death, and MACE) and exhibited a J-shaped curve. Conclusions: SHR is significantly associated with long-term all-cause death, CVD death, and MACE in CAD patients. Our findings highlight SHR can be used as a valuable tool for long-term prognosis risk stratification in CAD, potentially influencing clinical decision-making and patient management strategies.

Indexed as

Coronary Artery DiseaseGlycated HemoglobinHyperglycemiaRisk AssessmentAgedBlood GlucoseCardiovascular DiseasesChinaFemaleHumansInpatientsMaleMiddle AgedPatient AdmissionPredictive Value of TestsPrognosisBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanall-cause deathcardiovascular disease deathcoronary artery diseasemajor adverse cardiovascular eventsstress hyperglycemia ratio

Identifiers

PMID41036145
PMCPMC12479314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.